Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gongwin Biopharm Holdings CoROCO:6617 +8.37%57 Altman Z-Score is 27.73 as of Sep. 04, 2026, which is 30% below its 10-year median of 39.67. GuruFocus rates ROCO:6617 with a GF Score™ of 57/100. The stock has 5 warning signs investors should review. Among 930 Biotechnology companies, Gongwin Biopharm Holdings Co ranks better than 91.61% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 27.16 is strong.
Gongwin Biopharm Holdings Co has a Altman Z-Score of 27.73, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Gongwin Biopharm Holdings Co's Altman Z-Score or its related term are showing as below:
ROCO:6617'
s Altman Z-Score Range Over the Past 10 Years
Min: 15.99 Med: 39.67 Max: 183.86
Current: 27.16
During the past 13 years, Gongwin Biopharm Holdings Co's highest Altman Z-Score was 183.86. The lowest was 15.99. And the median was 39.67.
Gongwin Biopharm Holdings Co (ROCO:6617) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6617 vs VRTX, REGN, MRNA: Altman Z-Score Comparison
For the Biotechnology subindustry, Gongwin Biopharm Holdings Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gongwin Biopharm Holdings Co Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gongwin Biopharm Holdings Co's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Gongwin Biopharm Holdings Co's Altman Z-Score falls into.
Gongwin Biopharm Holdings Co Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Gongwin Biopharm Holdings Co (ROCO:6617) has a Altman Z-Score of 27.73 as of Sep. 04, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Gongwin Biopharm Holdings Co and its competitors. This is 30% below median its historical median of 39.67. Over the past decade, Gongwin Biopharm Holdings Co's Altman Z-Score has ranged from 15.99 to 183.86. According to the industry distribution chart, Gongwin Biopharm Holdings Co ranks #78 out of 930 companies in the Biotechnology industry, placing it in the top 8.4%.
Is Gongwin Biopharm Holdings Co's Altman Z-Score too high?
Gongwin Biopharm Holdings Co's current Altman Z-Score of 27.73 is 30% below median its 10-year median of 39.67. Over the past 10 years, this metric has ranged from a low of 15.99 to a high of 183.86. The Biotechnology industry median Altman Z-Score is 2.74. Gongwin Biopharm Holdings Co's value of 27.73 is 912% above this industry median. Based on the distribution chart, Gongwin Biopharm Holdings Co ranks #78 out of 930 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gongwin Biopharm Holdings Co has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Gongwin Biopharm Holdings Co's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gongwin Biopharm Holdings Co ranks #78 out of 930 companies for Altman Z-Score. This places Gongwin Biopharm Holdings Co in the top 8% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.74. Gongwin Biopharm Holdings Co's value of 27.73 is 912% above this benchmark. Historically, Gongwin Biopharm Holdings Co's own Altman Z-Score has ranged from 15.99 to 183.86 over the past decade. While the company's 10-year median is 39.67 vs. the industry median of 2.74, Gongwin Biopharm Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.74, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gongwin Biopharm Holdings Co's current Altman Z-Score of 27.73 is 912% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Gongwin Biopharm Holdings Co and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gongwin Biopharm Holdings Co's current Altman Z-Score is 27.73, which is 30% below median its own 10-year median of 39.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gongwin Biopharm Holdings Co stock overvalued right now?
Gongwin Biopharm Holdings Co (ROCO:6617) has a current Altman Z-Score of 27.73. The current Altman Z-Score is 27.73, which is 30% below median its 10-year median of 39.67 and 912% above the Biotechnology industry median of 2.74. Gongwin Biopharm Holdings Co's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Gongwin Biopharm Holdings Co (ROCO:6617), the current Altman Z-Score is 27.73 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gongwin Biopharm Holdings Co Ltd is a Taiwan-based biopharmaceutical company focused on developing novel anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma. The Group includes pharmaceutical research and development, drug testing, pharmaceutical technology consulting, biotechnology services, technology transfer, and the sale of new drugs.
57GF Score
Get the complete analysis for ROCO:6617
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6617 has been successfully added to your 
